Why true conservation requires letting Pfizer strip-mine Gabon's sacred iboga root

Deep in the central African rainforest, a slow-growing shrub called Tabernanthe iboga is quietly reaching maturity. For centuries, the Gabonese people have harvested its bitter root bark for use in complex ritual traditions. If you visit one of their temples today, you will find a scene of profound cultural resonance: people sitting shoulder to shoulder on a sandy floor, edged with candles beneath palm fronds hung from the rafters. Through the night, they swallow the raw iboga root to treat trauma, mental illness, and severe addiction. It is a beautiful, deeply moving tableau of indigenous spiritual practice. It is also, quite frankly, a horrifying failure of supply chain optimization.

Last November, while attending the COP climate summit in Dubai, I found myself sharing a bottle of sustainably sourced sparkling water with the chief lobbying officer of a major American pharmaceutical conglomerate. We had slipped away from a panel on global biodiversity frameworks, and as we looked out over the artificial archipelago, he began to weep. He showed me the preliminary clinical data on iboga’s potential to treat opioid dependency. The efficacy rates were staggering. Yet, his company’s stock was tumbling. Why? Because the Gabonese locals stubbornly refuse to let American venture capital aggressively monetize their sacred sacrament.

We are facing a crisis of gatekeeping, and for once, the perpetrators are the historically marginalized. The iboga plant represents a multi-billion-dollar therapeutic market, but it is currently being hoarded by the very people who discovered it, cultivated it, and understand how to use it safely. This is not just selfish; it is fundamentally anti-progress.

Let us examine the environmental reality of this situation. The Gabonese traditionalists claim they are living in harmony with the forest. But where is their ESG report? How can we possibly verify that a Bwiti spiritual leader in a remote village is maintaining net-zero emissions when they are literally burning unregulated candles in an unventilated palm-frond temple? It is environmental recklessness disguised as cultural purity.

True environmental stewardship requires industrialization. Contrast the chaotic, dirt-floored Gabonese temples with the pristine, carbon-neutral environment of a corporate extraction facility in New Jersey. In an American laboratory, the iboga root would be processed in sterile stainless-steel vats, its active alkaloids isolated, patented, and packaged into FDA-approved gelatin capsules. That is what real conservation looks like: taking something wild and free, and putting it behind a $4,000 paywall so that it can be properly managed by people who went to Wharton.

Furthermore, we must address the addiction treatment angle. The iboga root is widely believed to have immense potential for interrupting severe chemical dependencies. Who, I ask you, is better equipped to manage an addiction treatment than the American pharmaceutical industry? These companies have spent the last three decades meticulously cultivating one of the most robust, high-yield addiction markets in human history. They built the opioid crisis from the ground up. To deny them the cure to the very problem they pioneered is simply bad business. It is like refusing to let an arsonist sell you a fire extinguisher.

The wellness community is already calling iboga "the next ayahuasca," which should terrify us all. We must learn from our disastrous mishandling of ayahuasca. Thanks to a lack of aggressive early patenting, that sacred Amazonian vine remains tragically accessible to almost anyone willing to fly to Peru. We cannot let Tabernanthe iboga suffer the same fate. If we do not act now to corporatize this root, we risk a future where desperate people can just go to Gabon and be healed for free, entirely bypassing the American medical billing apparatus.

I spoke to a prominent healthcare venture capitalist recently—another off-the-record chat, because the mob simply will not allow us to speak the truth in public. He made a brilliant, sobering point over our lunch of endangered bluefin tuna. The real threat to global biodiversity isn't corporate extraction. The real threat is local people thinking they have a right to the flora they’ve lived alongside for millennia, simply because it grows in their backyards.

We are out of time, but go off. If the Gabonese truly respect the Tabernanthe iboga plant, they will immediately surrender all cultivation rights to a consortium of heavily subsidized American startups. It is the only way to ensure the root survives long enough to be synthetically replicated and ultimately rendered obsolete by a cheaper, more addictive chemical alternative.

Until we have the courage to forcibly integrate this sacred tradition into the NASDAQ, I will continue to advocate for the voiceless victims of this tragedy: the American executives who just want to heal the world, provided they secure exclusive distribution rights first.